(Q46147583)

19 December 2017

title

Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study (English)

1 reference

19 December 2017

8

A Colao

1 reference

19 December 2017

R S Auriemma

1

1 reference

19 December 2017

R Pivonello

2

1 reference

19 December 2017

M Galdiero

3

1 reference

19 December 2017

M C De Martino

4

1 reference

19 December 2017

M De Leo

5

1 reference

19 December 2017

G Vitale

6

1 reference

19 December 2017

G Lombardi

7

1 reference

19 December 2017

publication date

1 November 2008

1 reference

19 December 2017

Journal of Endocrinological Investigation

published in

1 reference

19 December 2017

volume

31

1 reference

19 December 2017

issue

11

1 reference

19 December 2017

page(s)

956-965

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/bf03345632

exact match

0 references

cites work

Guidelines for acromegaly management

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Primary medical therapy for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Growth-hormone and prolactin excess.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Lipids, risk factors and ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Hypertension in acromegaly and in the normal population: prevalence and determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Somatostatin analogs in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Cardiovascular effects of the somatostatin analog octreotide in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Effects of two different somatostatin analogs on glucose tolerance in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345632

Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion

21 January 2018

1 reference

12 December 2020

Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly

1 reference

12 December 2020

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

1 reference

12 December 2020

Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly

1 reference

12 December 2020

Effect of octreotide pretreatment on surgical outcome in acromegaly

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

1 reference

12 December 2020

Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly

1 reference

12 December 2020

A comparison of lanreotide and octreotide LAR for treatment of acromegaly

1 reference

12 December 2020

Prediction of efficacy of octreotide therapy in patients with acromegaly.

1 reference

12 December 2020

Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy

1 reference

12 December 2020

Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly

1 reference

12 December 2020

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345632

1 reference

19 December 2017

1 reference

19 December 2017